We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces
News

Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces

Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces
News

Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The sales force will remain focused on Pediatrics, Primary Care and Gastroenterology.
The Company today also announced that David Becker will resign his position as Chief Financial Officer, due to personal reasons, effective March 31, 2013. The Company has started a search to identify a new Chief Financial Officer. Upon naming a successor, Mr. Becker will serve the Company as a consultant in several areas, including manufacturing, over-the-counter products, and business development.

Cooper Collins, President and CEO of Pernix, said, “We closed the acquisition of Cypress and Hawthorn at the end of December, and we are rapidly making progress in the implementation of our integration plans. In addition, we appreciate the service that David has provided the Company, which included building our OTC product group and completing several key business development transactions that have broadened the scope of our business and expanded our portfolio of branded and generic products.”

Advertisement